局部硫糖肽滴眼液促进干燥应激干眼模型眼表黏蛋白分泌
研究在NOD.B10.H2b小鼠干燥应激干眼模型中评估局部硫糖肽(SOS)制剂疗效,发现4% SOS滴眼液可显著增加泪液分泌、恢复角膜上皮稳定,并增加结膜杯状细胞数量及MUC1、MUC4、MUC16和MUC5AC表达,且抗炎作用呈剂量依赖性。提示局部硫糖肽或可作为治疗干眼的新眼科药物材料。
要点
- 4% SOS滴眼液使干燥应激小鼠泪液分泌和角膜稳定恢复至基线水平。
- 4% SOS增加结膜杯状细胞数量及MUC1、MUC4、MUC16、MUC5AC表达。
- SOS制剂抗炎改善呈剂量依赖性。
核心结论
- 局部硫糖肽可增强干眼病眼表黏蛋白分泌,有望作为治疗干眼的新眼科药物材料。
研究设计与样本
- NOD.B10.H2b小鼠暴露于空气流10天并皮下注射氢溴酸东莨菪碱建立干燥应激干眼模型。
- 小鼠随机分为九组,包括四种SOS制剂和三種市售药物。
- 治疗10天后评估泪液分泌、上皮稳定、黏蛋白分泌和炎症。
主要发现
- 干燥应激显著降低泪液分泌和角膜上皮稳定性,并显著减少结膜杯状细胞和黏蛋白染色细胞数量。
- 局部4% SOS滴眼液显著增加泪液分泌和角膜稳定,恢复至基线水平。
- 局部4% SOS显著增加杯状细胞数量及MUC1、MUC4、MUC16和MUC5AC表达。
- SOS制剂以剂量依赖方式提供抗炎改善。
关键数值与推荐
- 局部4% SOS滴眼液使泪液分泌和角膜稳定恢复至基线水平。
- 局部4% SOS显著增加结膜杯状细胞数量及MUC1、MUC4、MUC16、MUC5AC表达。
临床怎么用
- 提示局部硫糖肽可能通过促进黏蛋白分泌和抗炎作用治疗干眼,但尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was the investigation of the effect of sulglycotide (SOS), a polysulfated glycopeptide derived from porcine duodenal mucin, for the treatment of dry eye disease. METHODS: NOD.B10.H2b mice were exposed to an air draft for 10 days, and, simultaneously, scopolamine hydrobromide was injected subcutaneously. The mice were randomly divided into nine groups as follows: four kinds of SOS formulations and three kinds of commercial medicine. After 10 days of treatment, we estimated the effect of treatment on tear production, epithelium stabilization, mucin secretion, and inflammation. RESULTS: The desiccation stress significantly decreased tear production and corneal epithelium stabilization, as well as markedly decreased the numbers of goblet cells and mucin-stained cells in conjunctiva. However, the topical 4% SOS eye drops markedly increased tear production and corneal stabilization, which recovered to baseline levels. In addition, topical 4% SOS significantly induced an increase in the numbers of goblet cells and the expression of membrane-associated mucins including MUC1, MUC4, and MUC16, as well as the gel-forming mucin, MUC5AC. Furthermore, SOS formulations provided anti-inflammatory improvement in a dose-dependent manner. CONCLUSIONS: In summary, we suggest that a new ophthalmic pharmaceutical formulation, topical sulglycotide, enhances the ocular mucin secretion in dry eye disease and can be used as a new ophthalmic pharmaceutical material to treat dry eye disease.
引用
- Lee H, Jeon S, Kim CE, et al. A New Ophthalmic Pharmaceutical Formulation, Topical Sulglycotide, Enhances the Ocular Mucin Secretion in Desiccation Stress-Mediated Dry Eye Disease. Invest Ophthalmol Vis Sci. 2019. PMID: 30901389. doi:10.1167/iovs.18-24935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。